Anti-TRAF2 antibody produced in rabbit，100UL，HPA009972-100UL，Sigma

General description

TRAF2 (TNF receptor associated factor 2) is one of the six members of the TRAF family. It is an adaptor protein, and is composed of a conserved TRAF domain in its C-terminal and a RING finger domain in its N-terminal. It also contains multiple zinc finger regions.

Immunogen

TNF receptor-associated factor 2 recombinant protein epitope signature tag (PrEST)

Application

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Biochem/physiol Actions

TRAF2 (TNF receptor associated factor 2) is recruited on activation of TNFR (tumor necrosis factor receptor) by TNF. It directly binds to TNFR2 and interacts with TNFR1 through TRADD (TNFR1-associated death domain protein). This protein activates JNK (c-jun N-terminal kinase) upon activation by ASK1 (apoptosis signal-regulating kinase 1). TRAF2 faciliates rapid vaccinia virus (VACV) entry and thus aids VACV replication. TRAF2 and RIP1 (receptor-interacting protein) up-regulation in leukocytes results in increased inflammatory responses in multiple sclerosis (MS) patients, and the elevation of this protein is seen in patients with relapsing-remitting multiple sclerosis (RRMS). The expression of this protein is linked with poor prognosis in activated B-cell (ABC)-like diffuse large B-cell lymphomas (DLBCL), where it activates NF-κB. It might also be the reason for chemoresistance in ABC-DLBCL.

Features and Benefits

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Other Notes

Corresponding Antigen APREST71912

Legal Information

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.